Innova Captab Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: INNOVACAP BSE: 544067
₹1159.80
Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #54 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Innova Captab Limited (this stock) 6,637 69.5 13.4% 33.0% 0.17% 70 0 50

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹6,957 Cr
EV / EBITDA
38.2x
EV / Sales
4.93x
Market cap / Sales
4.70x
Earnings yield
1.44%

Quarterly Financials

↑ Positive
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 403 Cr, up 38.4% YoY.

↑ Positive
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 32 Cr, up 58.0% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 400 43 32 ₹5.6000
March 31, 2026 358 28 21 ₹3.7000
Dec. 31, 2025 364 37 28 ₹4.8800
Sept. 30, 2025 290 19 14 ₹2.5000
June 30, 2025 287 27 20 ₹3.5500
March 31, 2025 243 23 17 ₹2.9900
Dec. 31, 2024 249 33 24 ₹4.2600
Sept. 30, 2024 240 34 26 ₹4.4800
June 30, 2024 227 30 22 ₹3.9000
March 31, 2024 198 26 20 ₹3.4500
Dec. 31, 2023 236 26 19 ₹3.2590
Sept. 30, 2023 212 20 14 ₹3.0200

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
Total income (before exceptional items)403361367294291247252244231204238214
Operating revenue400358364290287243249240227198236212
Other income333544345622
Operating expenses346320317261252214216207198175206185
Operating profit543947293528323328233126
Operating profit margin13.5%10.8%12.9%10.1%12.1%11.6%13.1%13.8%12.5%11.8%12.9%12.4%
Depreciation1099998333333
Interest443532000045
Exceptional items, gain / (loss)————————————
Profit before tax432837192723333430262620
Tax1179576898776
Net profit322128142017242622201914
EPS5.603.704.882.503.552.994.264.483.903.453.263.02
Net profit (TTM)958480768789928675———
EPS (TTM)16.6814.6313.9213.3015.2815.6316.0915.0913.63———

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year endedRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)
March 31, 2026 1,299 112 —
March 31, 2025 958 120 89
March 31, 2024 865 94 68

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24
Total income (before exceptional items) — — 1,314†975†—
Operating revenue — — 1,299958865
Other income — — 15†17†—
Operating expenses — — 1,149†836†—
Operating profit — — 150†122†—
Operating profit margin — — 11.5%†12.8%†—
Depreciation — — 37†17†—
Interest — — 15†2†—
Exceptional items, gain / (loss) — — 0†0†—
Profit before tax — — 11212094
Tax — — 28†30†—
Net profit — — 84†8968
EPS — — 14.63†15.63†—

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24
Operating margin11.5%†12.8%†—
EBIT margin9.8%†12.7%†—
PBT margin8.6%12.5%10.8%
Net margin6.4%†9.3%7.9%
Interest coverage8.25x†56.30x†—
Dividend payout13.7%†0.0%†—
Earnings retention86.3%†100.0%†—
Current ratio1.81x1.82x—
Quick ratio1.32x1.34x—
Debt to equity—0.40x—
Return on equity—11.0%—
Return on assets5.4%†6.6%—
Return on capital employed11.2%†11.4%†—
Asset turnover0.84x0.70x—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 — — -34 62 —
March 31, 2025 20 -100 84 161 -141
March 31, 2024 112 -472 368 277 -166

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 1,547 — — 105 216 750 414 1 647 204
March 31, 2025 1,365 813 756 84 245 529 290 15 637 140
March 31, 2024 — — — — — — — — — —

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.